These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 22156502)

  • 1. The scopolamine model of dementia: chronic transdermal administration.
    Brazell C; Preston GC; Ward C; Lines CR; Traub M
    J Psychopharmacol; 1989 Jan; 3(2):76-82. PubMed ID: 22156502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man.
    Preston GC; Brazell C; Ward C; Broks P; Traub M; Stahl SM
    J Psychopharmacol; 1988 Jan; 2(2):67-79. PubMed ID: 22155841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory and attention in patients with senile dementia of the Alzheimer type and in normal elderly subjects.
    Lines CR; Dawson C; Preston GC; Reich S; Foster C; Traub M
    J Clin Exp Neuropsychol; 1991 Sep; 13(5):691-702. PubMed ID: 1955525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual side-effects from transdermal scopolamine (hyoscine).
    Firth AY; Walker K
    Dev Med Child Neurol; 2006 Feb; 48(2):137-8. PubMed ID: 16417670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of drooling using transdermal scopolamine skin patches. A case report.
    Mato Montero A; Limeres Posse J; Tomás Carmona I; Fernández Feijoo J; Diz Dios P
    Med Oral Patol Oral Cir Bucal; 2008 Jan; 13(1):E27-30. PubMed ID: 18167476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing peripheral and central cholinergic system responses.
    Naranjo CA; Fourie J; Herrmann N; Lanctôt KL; Birt C; Yau KK
    J Psychiatry Neurosci; 2000 Sep; 25(4):325-36. PubMed ID: 11022397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of muscarinic and nicotinic receptor antagonists on attention and working memory.
    McQuail JA; Burk JA
    Pharmacol Biochem Behav; 2006 Dec; 85(4):796-803. PubMed ID: 17196638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal scopolamine: effects of single and repeated patches upon psychological task performance.
    Parrott AC
    Neuropsychobiology; 1987; 17(1-2):53-9. PubMed ID: 3627392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers.
    Molchan SE; Mellow AM; Hill JL; Weingartner H; Martinez R; Vitiello B; Sunderland T
    J Psychopharmacol; 1992 Jan; 6(4):489-500. PubMed ID: 22291397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic modulation, visual function and Alzheimer's dementia.
    Nobili L; Sannita WG
    Vision Res; 1997 Dec; 37(24):3559-71. PubMed ID: 9425531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aged dogs demonstrate both increased sensitivity to scopolamine impairment and decreased muscarinic receptor density.
    Araujo JA; Nobrega JN; Raymond R; Milgram NW
    Pharmacol Biochem Behav; 2011 Apr; 98(2):203-9. PubMed ID: 21238475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease.
    Shi J; Cong W; Wang Y; Liu Q; Luo G
    Drug Dev Ind Pharm; 2012 Jun; 38(6):752-61. PubMed ID: 22014311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
    Oki T; Toma-Okura A; Yamada S
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diphenyl diselenide improves scopolamine-induced memory impairment in mice.
    Souza AC; Brüning CA; Leite MR; Zeni G; Nogueira CW
    Behav Pharmacol; 2010 Sep; 21(5-6):556-62. PubMed ID: 20520530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SK-PC-B70M from Pulsatilla koreana improves scopolamine-induced impairments of memory consolidation and spatial working memory.
    Han CK; Park YH; Jin DQ; Hwang YK; Oh KB; Han JS
    Brain Res; 2007 Dec; 1184():254-9. PubMed ID: 17976545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.